Immunocore’s (IMCR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $100.00 target price on the stock.

Other equities research analysts have also recently issued reports about the company. Zacks Research cut Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Needham & Company LLC boosted their price objective on Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Jefferies Financial Group cut Immunocore from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $48.00 to $33.00 in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, January 22nd. Finally, UBS Group set a $55.00 price objective on Immunocore and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $60.89.

Immunocore Trading Down 0.8%

Shares of IMCR stock opened at $31.38 on Tuesday. Immunocore has a 12-month low of $27.06 and a 12-month high of $40.71. The company has a current ratio of 4.04, a quick ratio of 4.01 and a debt-to-equity ratio of 1.03. The stock’s 50-day moving average price is $31.68 and its 200-day moving average price is $33.73. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -44.83 and a beta of 0.83.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.60) earnings per share for the quarter. Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The company had revenue of $104.48 million for the quarter. Equities research analysts predict that Immunocore will post -0.94 EPS for the current fiscal year.

Insider Buying and Selling at Immunocore

In other Immunocore news, insider Leger Tina Amber St sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the transaction, the insider owned 1,119 shares in the company, valued at $36,199.65. The trade was a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bahija Jallal sold 11,474 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $371,183.90. Following the transaction, the chief executive officer owned 12,343 shares of the company’s stock, valued at $399,296.05. This trade represents a 48.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 19,137 shares of company stock worth $619,082 over the last 90 days. Company insiders own 10.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. purchased a new position in shares of Immunocore during the fourth quarter valued at approximately $47,000. XTX Topco Ltd bought a new position in Immunocore in the fourth quarter worth approximately $763,000. Voloridge Investment Management LLC bought a new position in Immunocore in the fourth quarter worth approximately $978,000. Vestal Point Capital LP bought a new position in Immunocore in the fourth quarter worth approximately $20,305,000. Finally, Virtus Investment Advisers LLC grew its stake in Immunocore by 48.9% in the fourth quarter. Virtus Investment Advisers LLC now owns 18,569 shares of the company’s stock worth $645,000 after purchasing an additional 6,097 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.